US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

Alector的产品管道中包括多种候选药物，例如AL001、AL002、AL003和AL101，正处于临床试验阶段。 在生物技术行业，创新是生死攸关的问题，而市场的敏感 ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

周二，Morgan Stanley调整了对Alector Inc. (NASDAQ:ALEC)股票的立场，将其评级从持平下调至减持。该公司还大幅下调了目标价格，将其从之前的10.00美元大幅下调至3.00美元。

Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, ...